Literature DB >> 807769

32P-therapy in polycythemia vera.

G Meuret, G Hoffmann, R Gmelin.   

Abstract

A group of 52 consecutive patients with polycythemia vera was submitted to long-term therapy with radioactive phosphorus (32P). Initial phase of therapy induced complete remissions (normalization of hematogram; spleen not palpable) in 45% of the patients, and partial remissions in the remaining 55%. During maintenance therapy of the complete remission group, mean remission time was about 3.5 years. Individual remission times ranged between 1 and 6 years. In the group of patients with incomplete remission, mean remission time increased with the progression of the disease due to gradual development of "spent" -polycythemia. In patients with splenomegaly, remission time was negatively correlated to spleen size. In both groups the increment of annual accumulated dose averaged 2.4 mCi 32P. When considering polycythemia related causes of death only, mean survival time attained 12 years after initial treatment with 32P. Acute leukemia occurred in 2 patients (4%).

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 807769     DOI: 10.1007/BF01468756

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  11 in total

1.  POLYCYTHAEMIA VERA: CLINICAL STUDIES ON A SERIES OF 127 PATIENTS MANAGED WITHOUT RADIATION THERAPY.

Authors:  J PERKINS; M C ISRAUELS; J F WILKINSON
Journal:  Q J Med       Date:  1964-10

Review 2.  POLYCYTHEMIA VERA AND LEUKEMIA--THE ROLE OF RADIATION TREATMENT. A STUDY OF 1222 PATIENTS.

Authors:  B MODAN; A M LILIENFELD
Journal:  Medicine (Baltimore)       Date:  1965-07       Impact factor: 1.889

3.  POLYCYTHEMIA VERA: AGE RELATIONSHIPS AND SURVIVAL.

Authors:  E E OSGOOD
Journal:  Blood       Date:  1965-09       Impact factor: 22.113

4.  Polycythemia vera. II. Course and therapy.

Authors:  P CALABRESI; O O MEYER
Journal:  Ann Intern Med       Date:  1959-05       Impact factor: 25.391

5.  The incidence of leukaemia in patients with polycythaemia vera treated by radioactive phosphorus.

Authors:  E M LEDLIE
Journal:  Clin Radiol       Date:  1960-04       Impact factor: 2.350

6.  The nature and treatment of polycythemia; studies on 263 patients.

Authors:  J H LAWRENCE; N I BERLIN; R L HUFF
Journal:  Medicine (Baltimore)       Date:  1953-09       Impact factor: 1.889

7.  Polycythaemia vera. Course and prognosis.

Authors:  A VIDEBAEK
Journal:  Acta Med Scand       Date:  1950

8.  A study of hematological complications occurring in patients with polycythemia vera treated with 32-P (based on a series of 296 patients).

Authors:  M Tubiana; R Flamant; E Attie; M Hayat
Journal:  Blood       Date:  1968-10       Impact factor: 22.113

9.  Leukemia in polycythemia vera. Relationship to splenic myeloid metaplasia and therapeutic radiation dose.

Authors:  J H Lawrence; H S Winchell; W G Donald
Journal:  Ann Intern Med       Date:  1969-04       Impact factor: 25.391

10.  Survival of polycythaemia vera patients treated with radioactive phosphorus.

Authors:  J B Harman; E M Ledlie
Journal:  Br Med J       Date:  1967-04-15
View more
  1 in total

1.  Present status of 32P-therapy in management of polycythemia vera.

Authors:  G Meuret
Journal:  Klin Wochenschr       Date:  1975-06-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.